KOSDAQBiotech & Pharma476040

Organoidsciences

₩4,585▲ 1.89%2026-11-18 close
Market Cap
₩30.2B
Turnover
₩86,067,299
Volume
20K
Shares out.
6.6M
PER
—
PBR
—
EPS
-₩2,836
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Grows, Losses Widen at Organoid Platform Firm

ORGANOID SCIENCES pairs an organoid evaluation platform with regenerative therapy development. Its 2025 revenue rose 23.2% to KRW 2.41 billion, but its operating loss widened to KRW 16.2 billion, and quarterly operating losses have continued through the third quarter of 2026.

  1. 1

    2025 revenue reached KRW 2.41 billion, up 23.2% year on year, while the operating loss widened to KRW 16.2 billion.

  2. 2

    After a low in the first quarter of 2026, revenue increased in the second and third quarters, reaching KRW 752 million in the third quarter.

  3. 3

    The company has posted losses for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026, with cumulative controlling-shareholder net losses of KRW 19 billion over the last four quarters.

  4. 4

    The revenue mix shifted from ODISEI service revenue in 2024 toward the research product organoEZ, which accounted for a larger share in the first three quarters of 2025, according to Kiwoom Securities and Eugene Investment & Securities reports.

  5. 5

    The 2027 domestic commercialization target for the regenerative therapy ATORM-C and the duration of the company's funding are the next items to verify.

02

Business structure

ORGANOID SCIENCES operates regenerative therapies and drug evaluation solutions built on organoids, which are three-dimensional organ models derived from stem cells.

Its businesses include the ATORM regenerative therapy platform, the ODISEI evaluation solution, the organoEZ research product line, contract development and manufacturing (CDMO), and precision medicine companion diagnostics.

The ATORM pipeline includes ATORM-C for intestinal organoid therapy and ATORM-S for salivary gland organoid therapy, and first-in-human results for ATORM-C were presented at ISCT 2026 in May 2026.

ODISEI predicts drug response by co-culturing tumor organoids with immune cells and the tumor microenvironment, and a 2025 report cited about 20 customer institutions, including Severance Hospital.

Kiwoom Securities estimated that in the first three quarters of 2025, ODISEI generated 44.3% (KRW 540 million) and the organoEZ research products generated 55.7% (KRW 660 million) of revenue of about KRW 1.2 billion.

Eugene Investment & Securities (December 2025) put ODISEI service revenue at about KRW 1.66 billion in 2024 and about KRW 500 million in the first three quarters of 2025.

Overseas, Germany's Lambda Biologics serves as the sales base for ODISEI-based CRO services in Europe and the United States, and the company also operates a US subsidiary and a Vietnam branch.

In March 2026 the research organization moved to Osong in Chungcheongbuk-do, while sales and management functions stayed in Pangyo. Hub Organoids, once a leading player, was acquired by the life sciences unit of Merck KGaA in December 2024, which marks a large science company entering this field.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩300M-₩3.9B−1220.5%
2025Q4₩1.2B-₩3.8B−313.3%
2026Q1₩100M-₩4.2B−2955.2%
2026Q2₩600M-₩4.4B−728.2%
2026Q3₩800M-₩4.3B−574.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2024₩2B-₩12.2B-₩11.2B−626.4%−73.4%69.3%
2025₩2.4B-₩16.2B-₩15.4B−673.2%−62.3%49.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a reported annual basis, revenue rose from KRW 1.95 billion in 2024 to KRW 2.41 billion in 2025, up 23.2% year on year. Over the same period the operating loss widened from KRW 12.2 billion to KRW 16.2 billion, and the operating margin moved from -626.4% to -673.2%.

The net loss attributable to controlling shareholders grew from KRW 11.2 billion to KRW 15.4 billion, and the consolidated net loss, including non-controlling interests, grew from KRW 11.5 billion to KRW 15.7 billion. The company has posted losses for two consecutive years, from 2024 through 2025.

A news report on its listing filing said the company had reported losses since its founding, with an accumulated deficit of KRW 91.66 billion. Because the operating loss grew faster than revenue, the profit structure did not improve.

At the end of 2025, total equity was KRW 24.8 billion, of which KRW 24.7 billion belonged to controlling shareholders, and total liabilities were KRW 12.3 billion; the debt-to-equity ratio fell from 69.3% in 2024 to 49.7% in 2025.

Operating cash flow outflow widened from -KRW 9.14 billion in 2024 to -KRW 14 billion in 2025. Quarterly revenue rose from KRW 320 million in the third quarter of 2025 to KRW 1.23 billion in the fourth quarter (up 283.4% quarter on quarter), then fell to KRW 144 million in the first quarter of 2026 (down 88.3%).

Revenue then rose to KRW 598 million in the second quarter (up 316.5%) and KRW 752 million in the third quarter (up 25.7% quarter on quarter and 134.8% year on year), marking two consecutive quarters of growth.

The sharp quarterly swings appear tied to a contract-based revenue structure, though the timing of individual contracts cannot be separated from the reported figures.

Quarterly operating losses were KRW 3.91 billion, KRW 3.84 billion, KRW 4.24 billion, KRW 4.35 billion and KRW 4.32 billion from the third quarter of 2025 through the third quarter of 2026, which is five consecutive quarters of losses, and they stayed between KRW 3.84 billion and KRW 4.35 billion.

The net loss attributable to controlling shareholders widened to KRW 6.72 billion in the second quarter of 2026 before narrowing to KRW 4.35 billion in the third quarter, and the cumulative figure for the last four quarters is KRW 19 billion.

Revenue growth has not yet been matched by a reduction in the cost base, which remains the main obstacle to a profit turnaround.

05

Industry analysis

The organoid market is expanding alongside the shift toward new approach methodologies (NAMs) that reduce animal testing.

After the US FDA emphasized moving away from animal testing, an anticancer drug candidate received FDA IND clearance in October 2025 based only on organoid data without animal studies, according to an Eugene Investment & Securities report.

In Korea, the introduction of alternative test methods is under way, and the Ministry of Food and Drug Safety (MFDS) became the first regulator in the world to issue a quality and nonclinical evaluation guideline for organoid-based cell therapy clinical trials.

The company said in November 2026 that it alone conducted the foundational research behind that guideline.

Only three companies in Korea's bio sector hold national advanced strategic technology designations, and ORGANOID SCIENCES was the first to receive one for organoid regenerative therapy, according to a 2025 report.

An amendment to the Advanced Regenerative Bio Act, in effect in 2025, allows clinical-stage therapies to be prescribed for serious and rare intractable diseases, which opened an earlier commercialization route for ATORM-C.

Brokers have also pointed out that standardization and validation of organoid-based evaluation methods will take time. In the evaluation market, Hub Organoids, once a leading firm, was acquired by a unit of Merck KGaA, a sign that capital and technology are converging as the market grows.

Policy infrastructure is also expanding, including the launch of the K-NAMs alternative testing platform in 2026.

In terms of position, ORGANOID SCIENCES lacks the large-scale production capacity of a major CDMO such as Samsung Biologics and instead concentrates on evaluation solutions and small regenerative therapy pipelines.

06

Outlook

The confirmed near-term agenda rests on two tracks: clinical progress for the regenerative therapy ATORM-C and global expansion of the evaluation platform.

According to the plan presented during the 2025 listing, ATORM-C was targeted for domestic hospital commercialization in 2027 under the Advanced Regenerative Bio Act, after researcher-led clinical studies are completed in 2026.

The same plan called for an IND filing with Korea's MFDS and the start of a Korean Phase 1 trial in 2026, an FDA IND filing in 2026, and completion of a global Phase 2 trial by 2028.

At Cell & Gene Meeting on the Mesa 2026 in October 2026, the company presented ATORM-C clinical results and the development direction of ATORM-S, a salivary gland organoid therapy.

On the ODISEI side, the company unveiled an organoid-based antibody-drug conjugate (ADC) evaluation platform at AACR 2026 in April 2026, and its subsidiary Podo Therapeutics presented clinical data.

In November 2026 the company appointed Vice President Lee Cheol-gyu and created a Sales division to oversee domestic and overseas sales and commercialization of ODISEI. A 2025 report suggested ODISEI revenue could rise to more than KRW 10 billion a year by 2027.

In its IPO filing, the company projected 2028 revenue of KRW 56.4 billion and net income of KRW 2.137 billion, a large gap from 2025 revenue of KRW 2.41 billion, which makes meeting those long-term targets the central item to track.

The company also presented its platform and global partnership discussions at the BioCentury-BayHelix China Healthcare Summit in Shanghai on November 2 to 4, 2026.

The items to check are the revenue mix and profit and loss in the 2026 annual report, whether clinical approvals proceed, and the timing of 2027 commercialization.

07

Valuation

PER
—
PBR
—
ROE
-73.3%
EPS
-₩2,836
BPS
—
Dividend per share
₩0

Because the most recent four quarters show net losses, the price-to-earnings ratio cannot be calculated. The company also pays no dividend, so there is little shareholder-return basis for valuation.

The market value therefore appears to rest more on pipeline progress and platform expansion expectations than on current earnings.

During the listing, analysts said the valuation burden at the offering price weighed on demand, and some pointed out that the offering price was set below the enterprise value at which early financial investors had invested.

Equity of KRW 24.7 billion attributable to controlling shareholders at the end of 2025 acts as a buffer against losses, but that buffer shrinks if losses continue. Price-to-book ratio shows the premium over net assets, and because operating losses persist, comparisons based on earnings multiples are difficult.

The gap between the 2028 revenue projection in the IPO filing and actual 2025 revenue sits at the center of the valuation discussion.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Regulatory shift could widen evaluation demand

After the FDA emphasized alternatives to animal testing, an anticancer candidate received IND clearance in October 2025 based only on organoid data. MFDS issued the world's first guideline for organoid-based cell therapies in November 2026, and the company independently conducted the underlying research. Bulls cite the possibility that demand for evaluation solutions widens as regulations change.

Customer base and quarterly recovery

According to a 2025 report, ODISEI counted about 20 customer institutions and more than 40 service contracts. Fourth-quarter 2025 revenue reached KRW 1.23 billion, up 283.4% quarter on quarter, and revenue rose in both the second and third quarters of 2026. The November 2026 creation of a dedicated sales division can be read as an effort to expand contract wins.

Academic progress in regenerative therapy trials

First-in-human results for ATORM-C were selected for the Top Scoring Asia Abstract Award at ISCT 2026 in May 2026. In October 2026 the company presented clinical results and the follow-on pipeline ATORM-S at a US cell and gene therapy event.

The domestic commercialization target is 2027, so whether clinical results translate into that schedule is central to the bullish case.

09

Bear factors

Widening losses and consecutive deficits

The operating loss widened from KRW 12.2 billion in 2024 to KRW 16.2 billion in 2025, with an operating margin of -673.2%. The net loss attributable to controlling shareholders grew to KRW 15.4 billion in 2025, and the cumulative figure for the last four quarters is KRW 19 billion. In the second quarter of 2026 that loss widened to KRW 6.72 billion, showing sizable quarterly volatility.

Quarterly revenue volatility and a wide gap to long-term targets

Revenue fell 88.3% to KRW 144 million in the first quarter of 2026 before recovering, but third-quarter 2026 revenue of KRW 752 million remained below the KRW 1.23 billion posted in the fourth quarter of 2025.

The IPO filing's 2028 revenue target of KRW 56.4 billion is far above 2025 revenue of KRW 2.41 billion, leaving substantial uncertainty about achieving it.

Funding needs and schedule slippage risk

Operating cash outflow widened to KRW 14 billion in 2025. During the listing review, the Financial Supervisory Service reportedly asked the company to supplement its filing, including on possible clinical schedule delays.

A brokerage analysis estimated cash of about KRW 25 billion at the end of 2025 and said the company could operate through 2027 given an annual cash burn near KRW 10 billion, which makes any new funding a key variable.

10

Risk factors

Clinical and regulatory timing

The 2025 plan set the approval for a treatment-purpose designation under the advanced regenerative medicine framework for the second half of 2026, with 2027 commercialization dependent on that approval and clinical results.

If efficacy and safety data fall short or approvals are delayed, the entire commercialization timeline could slip. Overseas IND filings and the global Phase 2 timeline carry similar uncertainty.

Financial strain and possible new funding

Cumulative controlling-shareholder net losses over the last four quarters total KRW 19 billion, and operating cash outflow reached KRW 14 billion in 2025. If cash burn continues at this level, new funding may be needed, which could dilute existing shareholders. With total equity of KRW 24.8 billion, financial headroom would shrink quickly if losses keep accumulating.

Pace of commercialization and competition

Brokers have noted that standardizing and validating organoid-based evaluation methods will take time. With Hub Organoids acquired by a unit of Merck KGaA, well-capitalized competitors have increased.

Because revenue is generated contract by contract, quarterly results can swing significantly depending on the timing and size of customer agreements.

11

What to watch next

  1. After December 2026 (date not fixed)

    Confirm whether the treatment-purpose approval under the advanced regenerative medicine framework, planned for the second half of 2026, has advanced, and whether the 2027 domestic commercialization timeline for ATORM-C holds.

  2. After December 2026 (date not fixed)

    Check whether the MFDS IND filing, the start of the Korean Phase 1 trial, and the planned 2026 FDA IND filing have been executed, since these steps lead to the 2028 global Phase 2 target.

  3. By late March 2027 (annual report filing deadline)

    Review in the 2026 annual report the revenue split between ODISEI and organoEZ, the operating loss, and operating cash flow, and whether the quarterly loss pattern persists on an annual basis.

  4. After the first quarter of 2027 (date not fixed)

    Track whether annual cash burn stays near the level underlying the brokerage view of operations through 2027, whether new funding is raised, and whether ODISEI contract wins increase after the sales reorganization.

12

Overall view

ORGANOID SCIENCES recorded 2025 revenue of KRW 2.41 billion, up 23.2% year on year, but its operating loss widened to KRW 16.2 billion.

It has posted losses for two consecutive years, from 2024 through 2025, and quarterly operating losses have continued for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026.

Revenue rose in both the second and third quarters of 2026, which is a positive sign, but quarterly operating losses stayed between KRW 3.84 billion and KRW 4.35 billion.

Bullish factors include the possibility of wider demand for evaluation solutions as regulations shift, clinical progress for ATORM-C, and global expansion. Bearish factors include continued losses, quarterly revenue volatility, the gap between long-term targets and actual results, and the possibility of new funding.

The debt-to-equity ratio fell from 69.3% in 2024 to 49.7% in 2025, but operating cash outflow widened to KRW 14 billion in 2025.

The next checkpoints are the profit and loss and cash flow in the 2026 annual report, domestic approval and commercialization timing for ATORM-C, and contract flow after the sales reorganization. This report is for information only and does not include a buy or sell opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. pharm.edaily.co.kr
  2. biztribune.co.kr
  3. etoday.co.kr
  4. biotimes.co.kr
  5. dailypharm.com
  6. investnews.co.kr
  7. butler.works
  8. m.news.nate.com
  9. pharm.edaily.co.kr
  10. eugenefn.com
  11. m.news.nate.com
  12. m.news.nate.com
  13. thebionews.net
  14. medipana.com
  15. etoday.co.kr
  16. hankyung.com
  17. m.news.nate.com
  18. biz.newdaily.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis